Terns Pharmaceuticals, Inc. (TERN)
NASDAQ: TERN · Real-Time Price · USD
52.83
-0.01 (-0.02%)
At close: Apr 23, 2026, 4:00 PM EDT
52.88
+0.05 (0.09%)
After-hours: Apr 23, 2026, 6:53 PM EDT
Terns Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
59
Market Cap
6.10B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 1.00M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 1.73B |
| Caris Life Sciences | 812.03M |
| TG Therapeutics | 616.29M |
| Mirum Pharmaceuticals | 521.31M |
| Rhythm Pharmaceuticals | 189.76M |
| Centessa Pharmaceuticals | 15.00M |
| CG Oncology | 4.04M |
TERN News
- 8 days ago - Are TERN, SLNO, WSR Obtaining Fair Deals for their Shareholders? - PRNewsWire
- 16 days ago - Merck Lowered Terns Pharmaceuticals Offer Price After Trial Data Review - Benzinga
- 16 days ago - Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc. - Business Wire
- 21 days ago - Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewsWire
- 4 weeks ago - Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst - Benzinga
- 4 weeks ago - Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline - CNBC
- 4 weeks ago - Merck boosts cancer portfolio with $6.7 billion buyout of Terns Pharma - Reuters
- 4 weeks ago - Merck Reaches Nearly $6 Billion Deal for Cancer Biotech Terns - WSJ